Lapatinib is an oral targeted cancer medicine (tyrosine kinase inhibitor) used to treat advanced or metastatic HER2-positive breast cancer. It is typically prescribed in combination with capecitabine or letrozole when other treatments have stopped working.
Lapatinib is an oral targeted cancer medicine (tyrosine kinase inhibitor) used to treat advanced or metastatic HER2-positive breast cancer. It is typically prescribed in combination with capecitabine or letrozole when other treatments have stopped working.
Image 1 of 1